Evaluation of the immune function assay in pediatric living donor liver transplantation

The immune function (ImmuKnow) assay is a measure of cell‐mediated immunity based on the peripheral CD4+ T cell ATP activity. The efficacy of ImmuKnow in pediatric LDLT is not well documented. The aim of this study was to assess the correlations between the ImmuKnow and the clinical status in pediat...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric transplantation 2015-03, Vol.19 (2), p.144-152
Main Authors: Fukuda, Akinari, Imadome, Ken-Ichi, Sakamoto, Seisuke, Shigeta, Takanobu, Uchida, Hajime, Matsunami, Masatoshi, Sasaki, Kengo, Kanazawa, Hiroyuki, Kawano, Fuyuko, Nakazawa, Atsuko, Fujiwara, Shigeyoshi, Kasahara, Mureo
Format: Article
Language:English
Subjects:
Adenosine Triphosphate - chemistry
Adolescent
CD4-Positive T-Lymphocytes
Child
Child, Preschool
Female
Graft Rejection
Humans
immune responses
Immune System
Immunity, Cellular - immunology
Infant
Infant, Newborn
infectious risk
Liver Failure - immunology
Liver Failure - surgery
Liver Transplantation - methods
living donor liver transplantation
Living Donors
Male
pediatric liver transplantation
Polymerase Chain Reaction
Reference Values
rejection
Retrospective Studies
T lymphocytes
T-Lymphocytes - cytology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The immune function (ImmuKnow) assay is a measure of cell‐mediated immunity based on the peripheral CD4+ T cell ATP activity. The efficacy of ImmuKnow in pediatric LDLT is not well documented. The aim of this study was to assess the correlations between the ImmuKnow and the clinical status in pediatric LDLT recipients. A total of 716 blood samples were obtained from 60 pediatric LDLT recipients (one month to 16 yr of age). The recipient's status was classified as follows: stable, infection, or rejection. The ImmuKnow values in the pediatric LDLT recipients with a clinically stable status had a lower immune response (IQR 85–297 ATP ng/mL) than that previously reported in adults. Meanwhile, the ImmuKnow values of the stable patients were not correlated with age. Furthermore, a significant difference was found in the ImmuKnow values between the bacterial or fungal infection and stable groups, but not between the CMV or EBV infection and stable groups. The ImmuKnow levels in the pediatric LDLT were lower than those observed in the adult LDLT. The proposed reference value is between 85 and 297 ATP ng/mL in pediatric LDLT recipients. We conclude that the ImmuKnow assay could be helpful for monitoring pediatric LDLT recipients with bacterial or fungal infections.
ISSN:1397-3142
1399-3046
DOI:10.1111/petr.12402